This customizable solution, a sequential chromogenic multiplex IHC, in addition with whole slide digital pathology analysis, allow to assess complex TME cells phenotyping on one FFPE tumor tissue section with up-to 7 biomarkers in order to provide valuable predictive and prognostic information, as well as insights on the underlying mechanisms of therapy response and resistance.
Our expertise in immuno-oncology and our IO Biomarkers Experts and scientists ensure a fast development of your project and provide you a dedicated support during all the different steps of the development.
HalioDx has a strong expertise in complex panels development, containing up-to 7 biomarkers each, for the identification of complex cell phenotypes.
Our image and data analysts ensure a standardized quantification of cell populations and the assessment of cells clustering as well as a proximity index.
The data collected on the various panels can be combined into an Immunogram, a multimodal analysis platform, providing a 360° view of the tumor microenvironment.
Immunosign® 15 and Immunosign® 21 for Clinical Research has been developed by HalioDx for Immune monitoring assay (pre and post treatment). Each signature is a custom gene panel composed of 15 and 21 predefined immune genes, respectively, applicable to most cancer types and stages for clinical investigations.
These proprietary algorithm gives you unsurpassed results in order to stratify patient into High or Low Immunosign® and explore immune orientation.
Gene expression and molecular diagnostic is in our DNA as we benefit from 20 years in successful molecular diagnostic developments on multiple platforms from QPCR to NGS.
Our NGS pipeline can fit perfectly your needs by providing molecular analysis of your samples from discovery to late stage clinical trials :
Starting from DNA
Starting from RNA
| || |
|All solid tumor cancers||All solid tumor cancers|
HalioDx provides a comprehensive offer combining information on Tumor Foreignness (TMB), Microsatellite Instability (MSI), T Cell Expansion (TCR Clonality) as well as key oncogenes mutations to better understand Immunotherapy efficacy and assess its impact on TME.
This technology provides a maximization of molecular data output from the same sample using RNA and DNA assays with a possible integration to our Immunogram, a multimodal analysis platform.
AACR2020 Abstract # 5970
In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
Validation of Brightplex®, a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment
HalioDx Biopharma Services
Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study